Can Inflammatory Indexes Predict the Severity of Mucosal Inflammation in Ulcerative Colitis?

Abstract

Aim: Inflammatory indexes can relate to disease activity in ulcerative colitis (UC). This study aimed to evaluate whether the inflammatory indexes of neutrophil-lymphocyte ratio (NLR), C-reactive protein (CRP)-albumin ratio (CAR), CRP-lymphocyte ratio (CLR), and systemic immune-inflammation index (SIII) might predict the severity of mucosal inflammation in UC. Material and Methods: This retrospective case-control study included 184 UC patients and 101 healthy controls. The Mayo clinical score and Mayo endoscopic score were used for the clinical and endoscopic features of UC. Truelove and Richards’s method for the severity of mucosal inflammation determined the histological activity index (HAI). Results: The inflammatory index values, were higher in UC patients compared to the control group (p=0.007 for NLR, and p<0.001 for the others). The patients having endoscopic, clinic, and histologically active disease had higher inflammatory index values than those in remission (p<0.001 for all). UC patients with extensive disease had higher inflammatory index values than the patients who had limited disease (p<0.001 for all). The HAI values were positively correlated to all inflammatory indexes, and the correlation was the strongest between the HAI and CLR (rho=0.737, p<0.001). Regarding HAI, the diagnostic accuracy of all inflammatory indexes for detecting the clinically active disease was statistically significant, and there was no significant difference between them in terms of diagnostic accuracy. Conclusion: The inflammatory indexes of NLR, CAR, CLR, and SII might predict the severity of histological inflammation in UC.

Keywords

• Ulcerative colitis
• inflammatory indexes
• mucosal inflammation.

İnflamatuar İndeksler Ülseratif Kolitte Mukozal İnflamasyonun Şiddetini Tahmin Edebilir mi?

Abstract

Amaç: İnflamatuar indekslerin ülseratif kolitte (ÜK) hastalık aktivitesi ile ilişkili oldukları bilinmektedir. Bu çalışma nötrofil-lenfosit oranı (NLR), C-reaktif protein (CRP)-albümin oranı (CAR), CRP-lenfosit oranı (CLR) ve sistemik immün-inflamasyon indeksini (SIII) içeren inflamatuar indekslerin ÜK’de mukozal inflamasyonun şiddetini tahmin edip edemeyeceğinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Bu retrospektif vaka kontrol çalışmasına 184 ÜK hastası ve 101 sağlıklı kontrol dahil edilmiştir. ÜK’nin klinik ve endoskopik özellikleri için Mayo klinik skoru ve Mayo endoskopik skoru kullanılmıştır. Mukozal inflamasyon şiddeti, Truelove ve Richards yöntemine göre histolojik aktivite indeksi (HAI) ile belirlenmiştir. Bulgular: ÜK hastalarında, inflamatuar indeks değerleri kontrol grubuna göre daha yüksek bulunmuştur (NLR için p=0,007 ve diğerleri için p<0,001). Endoskopik, klinik ve histolojik olarak aktif hastalığı olan vakaların inflamatuar indeks değerleri remisyonda olan vakalardan daha yüksek idi (tümü için p<0,001). Yaygın hastalığı olan ÜK hastalarının sınırlı hastalığı olan hastalardan daha yüksek inflamatuar indeks değerleri vardı (tümü için p<0,001). HAI değerleri tüm inflamatuar indekslerle pozitif korelasyon göstermekteydi ve en güçlü korelasyon HAI ile CLR arasında idi (rho=0,737; p<0,001). HAI ile ilişkili olarak, klinik olarak aktif hastalığın tespiti için tüm inflamatuvar indekslerin tanısal doğruluğu istatistiksel olarak anlamlıydı ve tanısal doğruluk açısından aralarında anlamlı bir fark yoktu. Sonuç: NLR, CAR, CLR ve SIII’i içeren inflamatuar indeskler, ÜK’de histolojik inflamasyonun şiddetini tahmin edebilir.

Keywords

• Ülseratif kolit
• inflamatuar indeksler
• mukozal inflamasyon

References

1. Osterman MT, Lichtenstein GR. Ulcerative colitis. In: Feldman M, Friedman SL, Brandt JL, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease, vol 2. Philadelphia: Elsevier Saunders; 2016. p.2023-61.
2. Chen F, Hu Y, Fan YH, Lv B. Clinical value of fecal calprotectin in predicting mucosal healing in patients with ulcerative colitis. Front Med (Lausanne). 2021;8:679264.
3. Słowińska-Solnica K, Pawlica-Gosiewska D, Gawlik K, Owczarek D, Cibor D, Pocztar H, et al. Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity. Arch Med Sci. 2021;17(1):252-7.
4. Feng W, Zhu L, Liu Y, Xu L, Shen H. C-reactive protein/albumin ratio and IL-6 are associated with disease activity in patients with ulcerative colitis. J Clin Lab Anal. 2023;37(3):e24843.
5. Zhang MH, Wang H, Wang HG, Wen X, Yang XZ. Effective immune-inflammation index for ulcerative colitis and activity assessments. World J Clin Cases. 2021;9(2):334-43.
6. Qin G, Tu J, Liu L, Luo L, Wu J, Tao L, et al. Serum albumin and C-reactive protein/albumin ratio are useful biomarkers of Crohn's disease activity. Med Sci Monit. 2016;22:4393-400.
7. Chen YH, Wang L, Feng SY, Cai WM, Chen XF, Huang ZM. The relationship between C-reactive protein/albumin ratio and disease activity in patients with inflammatory bowel disease. Gastroenterol Res Pract. 2020;2020:3467419.
8. Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, et al. Inflammatory indexes for assessing the severity and disease progression of ulcerative colitis: a single-center retrospective study. Front Public Health. 2022;10:851295.

9. Con D, Andrew B, Nicolaides S, van Langenberg DR, Vasudevan A. Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. Intest Res. 2022;20(1):101-13.
10. Feng W, Liu Y, Zhu L, Xu L, Shen H. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study. BMC Gastroenterol. 2022;22(1):485.
11. Furukawa S, Yagi S, Shiraishi K, Miyake T, Tange K, Hashimoto Y, et al. Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis. BMC Gastroenterol. 2022;22(1):39.
12. Header DA, Aboelwafa RA, Elkeleny MR, Bedewy ES, Ellakany AI. C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. Rev Gastroenterol Mex (Engl Ed). 2022;87(4):447-54.
13. Xie Y, Zhuang T, Ping Y, Zhang Y, Wang X, Yu P, et al. Elevated systemic immune inflammation index level is associated with disease activity in ulcerative colitis patients. Clin Chim Acta. 2021;517:122-6.
14. Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9(6):483-9.e3.
15. Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8(12):1582-97.
16. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J. 1956;1(4979):1315-8.
17. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32(2):174-8.
18. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47(3):404-9.
19. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451-9.
20. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol Hepatol 2005;19 Suppl A:5A-36A.
21. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol. 2003;23(11):2063-9.
22. Margaglione M, Cappucci G, Colaizzo D, Vecchione G, Grandone E, Di Minno G. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol. 2000;20(1):198-203.
23. Khan N, Patel D, Shah Y, Trivedi C, Yang YX. Albumin as a prognostic marker for ulcerative colitis. World J Gastroenterol. 2017;23(45):8008-16.
24. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474(7351):298-306.
25. Demir AK, Demirtas A, Kaya SU, Tastan I, Butun I, Sagcan M, et al. The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis. Kaohsiung J Med Sci. 2015;31(11):585-90.
26. Giuffrida P, Corazza GR, Di Sabatino A. Old and new lymphocyte players in inflammatory bowel disease. Dig Dis Sci. 2018;63(2):277-88.
27. Keleş A, Dagdeviren G, Yücel Celik O, Öztürk AC, Obut M, Çelen Ş, et al. Can inflammatory indices be used to predict adverse pregnancy outcomes in pregnant women with recurrent urinary tract infection? Duzce Med J. 2022;24(3):215-20.
28. Mosli MH, Feagan BG, Sandborn WJ, Dʼhaens G, Behling C, Kaplan K, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014;20(3):564-75.
29. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis, 2017;11(6):649-70.